148 related articles for article (PubMed ID: 12234990)
21. 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF): a potent inhibitor of purine biosynthesis.
Nutr Rev; 1990 Nov; 48(11):421-3. PubMed ID: 2080047
[No Abstract] [Full Text] [Related]
22. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
Lehman NL
Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
[TBL] [Abstract][Full Text] [Related]
23. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
25. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
26. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
[TBL] [Abstract][Full Text] [Related]
28. Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression.
Jansen M; Dykstra M; Lee JI; Stables J; Topley P; Knick VC; Mullin RJ; Duch DS; Smith GK
Biochem Pharmacol; 1994 Mar; 47(6):1067-78. PubMed ID: 8147906
[TBL] [Abstract][Full Text] [Related]
29. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.
Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3587-92. PubMed ID: 15848771
[TBL] [Abstract][Full Text] [Related]
32. In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.
Mullin RJ; Keith BR; Bigham EC; Duch DS; Ferone R; Heath LS; Singer S; Waters KA; Wilson HR
Biochem Pharmacol; 1992 Apr; 43(7):1627-34. PubMed ID: 1567484
[TBL] [Abstract][Full Text] [Related]
33. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.
Mitchell-Ryan S; Wang Y; Raghavan S; Ravindra MP; Hales E; Orr S; Cherian C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2013 Dec; 56(24):10016-10032. PubMed ID: 24256410
[TBL] [Abstract][Full Text] [Related]
35. Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells.
Lyons SD; Christopherson RI
Biochem Int; 1991 May; 24(1):187-97. PubMed ID: 1768258
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
37. 10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase.
Marsilje TH; Hedrick MP; Desharnais J; Capps K; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2003 Oct; 11(20):4503-9. PubMed ID: 13129586
[TBL] [Abstract][Full Text] [Related]
38. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
[TBL] [Abstract][Full Text] [Related]
39. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of 10-CF3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Desharnais J; Hwang I; Zhang Y; Tavassoli A; Baboval J; Benkovic SJ; Wilson IA; Boger DL
Bioorg Med Chem; 2003 Oct; 11(20):4511-21. PubMed ID: 13129587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
